SPAK kinase inhibitors as neuroprotective agents
AssigneesThe United States Government as represented by the Department of Veterans Affairs, University of Pittsburgh of the Commonwealth of Higher Education, Xiaman University, University of Exeter
InventorsDandan Sun, Xianming Deng, Jinwei Zhang, Mohammad Iqbal Hossain Bhuiyan, Bradley J. Molyneaux
Life of this patent
Estimating the term…
Abstract
The present disclosure is concerned with N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds that are capable of inhibiting SPAK kinase function, methods of treating hypoxic brain injuries due to, for example, ischemic stroke. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Claims20
A method for treating a hypoxic brain injury in a subject, the method comprising the step of administering to the subject an effective amount of at least one compound selected from:
- or a pharmaceutically acceptable salt thereof.
A method for treating a hypoxic brain injury associated with dysregulation of SPAK kinase in a subject, the method comprising the step of administering to the subject an effective amount of a compound having a structure:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.